Monitoring of CD3(+) T-cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation
Copyright © 2013 Elsevier Inc. All rights reserved..
AIM: Although antithymocyte globulin (ATG) has been used for years, its ideal dose and administration period is obscure. Herein, we sought to use the CD3(+) cell count to detect the optimal ATG dosage.
MATERIAL AND METHODS: Twenty-one patients who underwent cadaveric donor renal transplantation from January 2009 to January 2012 received a 1 mg/kg ATG initial dose at the time of the operation. Patients were randomized into 2 cohorts. Group 1 (n = 11) received ATG according to the clinical and total lymphocyte count and group 2 (n = 10), the dose was tailored according to the CD3(+) cell count. We compared the total and daily ATG dosages, ATG administration period, side effects of ATG, the number of days to a serum creatinine level <2 mg/dL, graft function at 3 months, acute rejection episodes, infection rates, costs of CD3(+) analysis, and ATG amounts.
RESULTS: Both groups showed similar gender, age, and human leukocyte antigen matching data. There was no difference in presensitizing events or panel-reactive antibody class 1 and 2 levels. The number of days to a serum creatinine level of <2 mg/dL was 11 ± 1.5 for group 1 versus 10.4 ± 0.8 for group 2 (P = .45). Between groups 1 and 2, there was a significant difference between the mean total (P = .031) and mean daily ATG dosages (P = .006). We used a total dose of 3800 mg ATG for group 1 and 2200 mg for group 2 and for the group 2 who underwent 43 CD3(+) cell counts. The expenditure per patient was 20% higher among group 1 than group 2.
CONCLUSION: Determination of appropriate ATG dosages by CD3(+) cell counts was useful, reliable, and cost effective.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Transplantation proceedings - 45(2013), 3 vom: 26. Apr., Seite 929-31 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ata, P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.10.2013 Date Revised 16.11.2017 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.transproceed.2013.02.092 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM227027523 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM227027523 | ||
| 003 | DE-627 | ||
| 005 | 20231224072738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.transproceed.2013.02.092 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0756.xml |
| 035 | |a (DE-627)NLM227027523 | ||
| 035 | |a (NLM)23622590 | ||
| 035 | |a (PII)S0041-1345(13)00281-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ata, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monitoring of CD3(+) T-cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2013 | ||
| 500 | |a Date Revised 16.11.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 Elsevier Inc. All rights reserved. | ||
| 520 | |a AIM: Although antithymocyte globulin (ATG) has been used for years, its ideal dose and administration period is obscure. Herein, we sought to use the CD3(+) cell count to detect the optimal ATG dosage | ||
| 520 | |a MATERIAL AND METHODS: Twenty-one patients who underwent cadaveric donor renal transplantation from January 2009 to January 2012 received a 1 mg/kg ATG initial dose at the time of the operation. Patients were randomized into 2 cohorts. Group 1 (n = 11) received ATG according to the clinical and total lymphocyte count and group 2 (n = 10), the dose was tailored according to the CD3(+) cell count. We compared the total and daily ATG dosages, ATG administration period, side effects of ATG, the number of days to a serum creatinine level <2 mg/dL, graft function at 3 months, acute rejection episodes, infection rates, costs of CD3(+) analysis, and ATG amounts | ||
| 520 | |a RESULTS: Both groups showed similar gender, age, and human leukocyte antigen matching data. There was no difference in presensitizing events or panel-reactive antibody class 1 and 2 levels. The number of days to a serum creatinine level of <2 mg/dL was 11 ± 1.5 for group 1 versus 10.4 ± 0.8 for group 2 (P = .45). Between groups 1 and 2, there was a significant difference between the mean total (P = .031) and mean daily ATG dosages (P = .006). We used a total dose of 3800 mg ATG for group 1 and 2200 mg for group 2 and for the group 2 who underwent 43 CD3(+) cell counts. The expenditure per patient was 20% higher among group 1 than group 2 | ||
| 520 | |a CONCLUSION: Determination of appropriate ATG dosages by CD3(+) cell counts was useful, reliable, and cost effective | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antilymphocyte Serum |2 NLM | |
| 650 | 7 | |a CD3 Complex |2 NLM | |
| 700 | 1 | |a Kara, M |e verfasserin |4 aut | |
| 700 | 1 | |a Özdemir, E |e verfasserin |4 aut | |
| 700 | 1 | |a Canbakan, M |e verfasserin |4 aut | |
| 700 | 1 | |a Gökçe, A M |e verfasserin |4 aut | |
| 700 | 1 | |a Bayraktar, F A |e verfasserin |4 aut | |
| 700 | 1 | |a Şahin, G |e verfasserin |4 aut | |
| 700 | 1 | |a Özel, L |e verfasserin |4 aut | |
| 700 | 1 | |a Titiz, M I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation proceedings |d 1969 |g 45(2013), 3 vom: 26. Apr., Seite 929-31 |w (DE-627)NLM000011029 |x 1873-2623 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2013 |g number:3 |g day:26 |g month:04 |g pages:929-31 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.transproceed.2013.02.092 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2013 |e 3 |b 26 |c 04 |h 929-31 | ||